Devices@FDA

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T06:40:13.662Z • Permanent link

Regulatory scrutiny is intensifying on the burgeoning field of implantable medical devices. On March 10, 2023, a U.S. District Court in Washington D.C. issued a ruling that could have far-reaching implications for the global medical device industry. The case, brought by the consumer advocacy group Public Citizen, challenged the FDA's approval process for the "Smart Contact Lens" developed by Mojo Vision, a Silicon Valley-based startup. Mojo Vision's device, touted as a future of vision care, is essentially a microchip embedded in a contact lens that enables users to access the internet and send messages via a smartphone app. According to Public Citizen, the FDA's decision to grant the device "deemed substantial equivalence" to an existing contact lens may have compromised public safety.

Mojo Vision's CEO, Don Lieberman, has dismissed the ruling, stating that the FDA's actions were "standard procedure." However, Public Citizen's lawyer, Robin S. Rudow, argued that the FDA's approval process was flawed and that Mojo Vision's device poses significant health risks to consumers. The ruling has sent shockwaves through the medical device industry, with many experts calling for greater transparency and accountability in the FDA's approval process.

Mojo Vision's device is just one example of the growing number of implantable medical devices that are being developed and approved by the FDA. In recent years, the agency has seen a surge in applications for devices such as pacemakers, implantable cardioverter-defibrillators, and brain-computer interfaces. While these devices have the potential to revolutionize healthcare, they also carry significant risks, including the possibility of malfunction or adverse reactions.

The implications of the Mojo Vision ruling are far-reaching, with potential consequences for the global medical device industry. Companies such as Medtronic, Boston Scientific, and Abbott are among those that have developed implantable devices that are subject to the FDA's approval process. If the agency's approval process is deemed inadequate, these companies could face significant regulatory scrutiny and potential liability. Research communities and markets are also likely to be impacted, as investors and consumers become increasingly wary of devices that have not undergone rigorous testing.

The FDA's approval process for implantable devices is also likely to be subject to increased scrutiny, with calls for greater transparency and accountability. In response to the Mojo Vision ruling, some lawmakers are calling for reforms to the FDA's approval process, including the requirement for more detailed pre-market testing and the establishment of an independent review board to oversee device approvals. While these reforms may help to mitigate the risks associated with implantable devices, they also carry the risk of slowing the development and approval of innovative new technologies.

The Mojo Vision ruling is part of a larger pattern of regulatory scrutiny in the medical device industry. In recent years, there have been several high-profile cases of devices being recalled or facing regulatory action due to concerns over safety and efficacy. For example, in 2020, the FDA issued a warning letter to Johnson & Johnson over its DePuy Synthes Orthopaedics' metal-on-metal hip replacement devices, which were found to be associated with a high rate of complications. Similarly, in 2022, the FDA issued a recall of certain medical devices manufactured by Becton Dickinson and Company due to concerns over contamination.